AstraZeneca tables $440m for Spirogen, signs ADC deal
This article was originally published in Scrip
Executive Summary
AstraZeneca has acquired the UK cancer drug developer Spirogen, as well as signing a deal with ADC Therapeutics. Both firms are majority owned by Auven Therapeutics, a hybrid firm focused on drug development but structured as a private equity fund. The deal brings AstraZeneca technology that allows cytotoxic warheads to be attached to cancer-targeting antibodies.